Incyte Corp

Incyte Corp Stock Forecast & Price Prediction

Live Incyte Corp Stock (INCY) Price
$75.92

26

Ratings

  • Buy 12
  • Hold 13
  • Sell 1
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$75.92

P/E Ratio

843.56

Volume Traded Today

$1.3M

Dividend

Dividends not available for INCY

52 Week High/low

83.95/50.35

Incyte Corp Market Cap

$14.63B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $INCY ๐Ÿ›‘

Before you buy INCY you'll want to see this list of ten stocks that have huge potential. Want to see if INCY made the cut? Enter your email below

INCY Summary

Based on ratings from 26 stock analysts, the Incyte Corp stock price is expected to increase by 3.14% in 12 months. This is calculated by using the average 12-month stock price forecast for Incyte Corp. The lowest target is $52 and the highest is $97. Please note analyst price targets are not guaranteed and could be missed completely.

INCY Analyst Ratings

Incyte Corp has a total of 26 Wall St Analyst ratings. There are 12 buy ratings, 13 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Incyte Corp will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

INCY stock forecast by analyst

These are the latest 20 analyst ratings of INCY.

Analyst/Firm

Rating

Price Target

Change

Date

Brian Abrahams
RBC Capital

Sector Perform

$74

Maintains

Nov 19, 2024
Eric Schmidt
Cantor Fitzgerald

Neutral


Reiterates

Nov 19, 2024
Brian Abrahams
RBC Capital

Sector Perform

$80

Maintains

Nov 14, 2024
Vikram Purohit
Morgan Stanley

Equal-Weight

$69

Maintains

Oct 30, 2024
Tazeen Ahmad
B of A Securities

Buy

$90

Upgrade

Oct 30, 2024
Jay Olson
Oppenheimer

Outperform

$82

Maintains

Oct 30, 2024
Evan Seigerman
BMO Capital

Underperform

$52

Reiterates

Oct 30, 2024
David Lebowitz
Citigroup

Buy

$97

Maintains

Oct 30, 2024
Derek Archila
Wells Fargo

Equal-Weight

$68

Maintains

Oct 30, 2024
Salveen Richter
Goldman Sachs

Neutral

$70

Maintains

Oct 30, 2024
Jessica Fye
JP Morgan

Neutral

$71

Maintains

Oct 30, 2024
Brian Abrahams
RBC Capital

Sector Perform

$72

Maintains

Oct 30, 2024
Jessica Fye
JP Morgan

Neutral

$65

Maintains

Oct 23, 2024
Derek Archila
Wells Fargo

Equal-Weight

$62

Maintains

Oct 10, 2024
Andy Chen
Wolfe Research

Outperform


Initiates

Oct 1, 2024
Srikripa Devarakonda
Truist Securities

Hold

$74

Downgrade

Sep 18, 2024
Reni Benjamin
JMP Securities

Market Perform


Reiterates

Sep 17, 2024
Michael Schmidt
Guggenheim

Buy

$92

Maintains

Sep 16, 2024
Eric Schmidt
Cantor Fitzgerald

Neutral


Reiterates

Sep 16, 2024
Tazeen Ahmad
B of A Securities

Neutral

$68

Maintains

Sep 16, 2024

INCY Company Information

What They Do: Biopharmaceutical company specializing in oncology therapeutics.

Business Model: Incyte Corporation generates revenue primarily through the discovery, development, and commercialization of innovative therapeutics targeting hematology/oncology and inflammation. The company markets several key drugs, including JAKAFI and MONJUVI, to specialty, retail, and hospital pharmacies, as well as distributors and wholesalers.

Other Information: Incyte has a robust pipeline of clinical-stage products, with several therapies in various phases of clinical trials. The company maintains strategic partnerships through collaboration and license agreements with major pharmaceutical firms like Novartis and Lilly, which can enhance its research capabilities and market reach. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte is well-positioned in the biopharmaceutical sector, focusing on unmet medical needs.
INCY
Incyte Corp (INCY)

When did it IPO

1993

Staff Count

2,524

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Herve Hoppenot

Market Cap

$14.63B

Incyte Corp (INCY) Financial Data

In 2023, INCY generated $3.70B in revenue, which was a increase of 8.87% from the previous year. This can be seen as a signal that INCY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$2.67B

Revenue From 2021

$2.99B

11.98 %
From Previous Year

Revenue From 2022

$3.39B

13.67 %
From Previous Year

Revenue From 2023

$3.70B

8.87 %
From Previous Year
  • Revenue TTM $4.08B
  • Operating Margin TTM 15.0%
  • Gross profit TTM $3.44B
  • Return on assets TTM -0.1%
  • Return on equity TTM 0.8%
  • Profit Margin 0.8%
  • Book Value Per Share 16.45%
  • Market capitalisation $14.63B
  • Revenue for 2021 $2.99B
  • Revenue for 2022 $3.39B
  • Revenue for 2023 $3.70B
  • EPS this year (TTM) $0.09

Incyte Corp (INCY) Latest News

News Image

Thu, 05 Dec 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations following its decision to pause enrollment in a Phase 2 study due to toxicology findings.

Why It Matters - The investigation into Incyte Corporation for potential securities law violations and the pause in its drug trial could significantly impact stock performance and investor confidence.

News Image

Fri, 06 Dec 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - Levi & Korsinsky has launched an investigation into Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations after the company paused enrollment in a drug study due to toxicity concerns.

Why It Matters - The investigation into Incyte Corporation signals potential legal risks and regulatory scrutiny, which may impact stock performance and investor confidence in the company.

News Image

Fri, 06 Dec 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Incyte has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).

Why It Matters - Incyte's inducement grants signal potential new hiring or retention efforts, which could impact future growth and operational performance, influencing investor sentiment and stock valuation.

News Image

Mon, 02 Dec 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations after it paused enrollment in a Phase 2 study for its drug INCB000262 due to toxicology concerns.

Why It Matters - The investigation into Incyte Corporation and the paused drug trial raise concerns about potential regulatory issues and financial implications, which could impact stock performance and investor confidence.

News Image

Tue, 03 Dec 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations following the pause of enrollment in a Phase 2 study of its drug INCB000262 due to toxicology concerns.

Why It Matters - The investigation into Incyte Corporation may indicate potential legal issues and regulatory scrutiny, raising concerns about the company's future performance and stock viability.

News Image

Wed, 04 Dec 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations after the company paused enrollment in a Phase 2 study due to toxicology concerns.

Why It Matters - The investigation into Incyte may indicate potential legal issues and regulatory scrutiny, impacting stock performance and investor confidence in the company's future prospects.

...

INCY Frequently asked questions

The highest forecasted price for INCY is $97 from at JMP Securities.

The lowest forecasted price for INCY is $52 from Evan Seigerman from BMO Capital

The INCY analyst ratings consensus are 12 buy ratings, 13 hold ratings, and 1 sell ratings.